Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial-Reference-Cited by-同舟云学术

Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial

Published:2018-02-24 Issue:5 Volume:93 Page:E125-E127
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Wierzbowska Agnieszka¹^ORCID,Wawrzyniak Ewa¹,Pluta Agnieszka¹,Robak Tadeusz¹,Mazur Grzegorz J.²,Dmoszynska Anna³,Cermak Jaroslav⁴,Oriol Albert⁵,Lysak Daniel⁶,Arthur Chris⁷,Doyle Margaret⁸,Xiu Liang⁹,Ravandi Farhad¹⁰,Kantarjian Hagop M.¹⁰^ORCID

Affiliation:

1. Department of Hematology; Medical University of Lodz; Lodz Poland

2. Department of Internal Disease; Wroclaw Medical University; Wroclaw Poland

3. Department of Haematooncology and Bone Marrow Transplantation; Medical University of Lublin; Lublin Poland

4. Clinical Hematology, Institute of Hematology and Blood Transfusion; Prague 2 Czech Republic

5. Institut Català d'Oncologia, Institut Josep Carreras,Hospital Germans Trias i Pujol; Barcelona Spain

6. Department of Hematology and Oncology, Medical School and Teaching Hospital in Plzen; Charles University in Prague; Plzen Czech Republic

7. Haematology Department; Royal North Shore Hospital; St Leonards New South Whales Australia

8. EMEA Medical Affairs, Janssen Sciences; Ireland

9. Janssen Research & Development LLC; Raritan New Jersey

10. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

Funder

Janssen Pharmaceutical Companies of Johnson & Johnson in Europe

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25062/fullpdf

Reference5 articles.

1. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype;Breems;J Clin Oncol.,2008

2. Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype-retrospective analysis of Polish Adult Leukemia Group (PALG). Leuk;Wierzbowska;Lymphoma.,2017

3. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy;Lübbert;Haematologica.,2012

4. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia;Kantarjian;J Clin Oncol.,2012

5. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group;Lübbert;Ann Hematol.,2016

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy;Leukemia Research;2023-04

2. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review;Future Oncology;2023-04

3. Comparison between azacitidine and decitabine as front-line therapy in elderly treatment naïve Acute Myeloid Leukemia not eligible for intensive chemotherapy;2022-08-24

4. The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia;Advances in Therapy;2021-11-16

5. Log reduction of leukemic cells and minimal residual disease by flow cytometry represent effective predictors of clinical outcome in elderly patients with acute myeloid leukemia;Cytometry Part B: Clinical Cytometry;2021-05-13